Trial Profile
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2024
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary) ; Capivasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Sapitinib (Primary) ; Savolitinib (Primary) ; Selumetinib (Primary) ; Vandetanib (Primary) ; Vistusertib (Primary) ; Erlotinib; Gemcitabine; Pemetrexed
- Indications Liver metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SAFIR02_Lung
Most Recent Events
- 04 Jun 2024 Results (n=56) assessing Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 09 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Results assessing association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer treated with maintenance durvalumab presented at the 59th Annual Meeting of the American Society of Clinical Oncology